Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The time to offer treatments for COVID-19.
Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, Ditmore S, Rendell M, Varon J, Dubé M, Nanda N, In G, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer DE, Ehresmann G, Peng D, Smogorewski M, Armstrong A, Dasgupta R, Sattler F, Brennan-Rieder D, Mussini C, Mitja O, Soriano V, Peschanski N, Hayem G, Confalonieri M, Piccirillo MC, Lobo-Ferreira A, Bello Rivero I, Turkia M, Vinjevoll EH, Griffin D, Hung IF. Ngo BT, et al. Among authors: bello rivero i. Expert Opin Investig Drugs. 2021 May;30(5):505-518. doi: 10.1080/13543784.2021.1901883. Epub 2021 Apr 23. Expert Opin Investig Drugs. 2021. PMID: 33721548 Free PMC article. Review.
Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.
Hernández-Bernal F, García-García I, González-Delgado CA, Valenzuela-Silva C, Soto-Hernández R, Ducongé J, Cervantes-Llano M, Blanco-Garcés E, Rodríguez V, García-Vega Y, Bello-Rivero I, Olivera-Ruano L, López-Saura P. Hernández-Bernal F, et al. Among authors: bello rivero i. Biopharm Drug Dispos. 2005 May;26(4):151-9. doi: 10.1002/bdd.445. Biopharm Drug Dispos. 2005. PMID: 15799006 Clinical Trial.
Construction, purification, and characterization of a chimeric TH1 antagonist.
Bello-Rivero I, Torrez-Ruiz Y, Blanco-Garcés E, Pentón-Rol G, Fernández-Batista O, Javier-González L, Gerónimo-Perez H, López-Saura P. Bello-Rivero I, et al. BMC Biotechnol. 2006 May 22;6:25. doi: 10.1186/1472-6750-6-25. BMC Biotechnol. 2006. PMID: 16716222 Free PMC article.
Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study.
Milanés-Virelles MT, García-García I, Santos-Herrera Y, Valdés-Quintana M, Valenzuela-Silva CM, Jiménez-Madrigal G, Ramos-Gómez TI, Bello-Rivero I, Fernández-Olivera N, Sánchez-de la Osa RB, Rodríguez-Acosta C, González-Méndez L, Martínez-Sánchez G, López-Saura PA; MACGAM Study Group. Milanés-Virelles MT, et al. Among authors: bello rivero i. BMC Infect Dis. 2008 Feb 11;8:17. doi: 10.1186/1471-2334-8-17. BMC Infect Dis. 2008. PMID: 18267006 Free PMC article. Clinical Trial.
Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.
Pentón-Rol G, Cervantes-Llanos M, Cabrera-Gómez JA, Alonso-Ramírez R, Valenzuela-Silva C, Rodríguez-Lara R, Montero-Casimiro E, Bello-Rivero I, López-Saura P. Pentón-Rol G, et al. Among authors: bello rivero i. Int Immunopharmacol. 2008 Jun;8(6):881-6. doi: 10.1016/j.intimp.2008.02.003. Epub 2008 Mar 5. Int Immunopharmacol. 2008. PMID: 18442793
Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA; FarmaPEG Study Group. García-García I, et al. Among authors: bello rivero i. BMC Pharmacol. 2010 Nov 23;10:15. doi: 10.1186/1471-2210-10-15. BMC Pharmacol. 2010. PMID: 21092287 Free PMC article. Clinical Trial.
18 results